









市場行情
/
股票
/
nasdaq-mltx
/

MoonLake Immunotherapeutics

MLTX



查看詳細走勢圖

13.830USD

-0.040-0.29%

收盤 12/26, 16:00（美東）報價延遲15分鐘

881.03M總市值

虧損本益比TTM



MoonLake Immunotherapeutics

13.830

-0.040-0.29%

概覽公司財務分析

概覽

公司

財務

分析

盤中分時

1分

30分

1小時

日k

週k

月k

日k

今天

-0.29%

5天

+3.29%

1月

+0.22%

6月

-70.90%

今年開始到現在

-74.46%

1年

-75.02%

查看詳細走勢圖

TradingKey 股票評分

由於缺少必要的數據，暫時無法對該公司進行評分

MoonLake Immunotherapeutics新聞

即將為您帶來更多新聞，敬請期待。。。

財務指標

每股收益

由於公司未披露，未能獲取相關數據

營業總收入

由於公司未披露，未能獲取相關數據

MoonLake Immunotherapeutics簡介

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

公司代碼MLTX

公司MoonLake Immunotherapeutics

CEOSantos Da Silva (Jorge)

網址https://moonlaketx.com/